Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Shujing Shen"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThis retrospective study evaluates the efficacy of camrelizumab combined with anlotinib versus chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) undergoing second-line treatment.MethodsData were sourced from m
Externí odkaz:
https://doaj.org/article/777c5109fd97437f9bd9d587d8ad9f52
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The impact of immune checkpoint inhibitors (ICIs) based treatments on non-small cell lung cancers (NSCLCs) with RET fusions remains poorly understood. Methods We screened patients with RET fusions at the First Affiliated Hospital
Externí odkaz:
https://doaj.org/article/8ea25916d815463c8b5343bf26a27f79
Publikováno v:
Cancer Medicine, Vol 11, Iss 23, Pp 4491-4500 (2022)
Abstract Background Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real‐world data of ALK TKIs remain a major concern. Method
Externí odkaz:
https://doaj.org/article/c41c8d0da1ce4330976c2dfc38f0964d
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: The deletion of exon 19 and the Leu858Arg mutation of exon 21 are the most frequently observed mutations in the epidermal growth factor receptor (EGFR) gene, and patients with these mutations have shown significant benefits from EGFR-tyro
Externí odkaz:
https://doaj.org/article/660e0cccbf58497b8b82dea235713660
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Externí odkaz:
https://doaj.org/article/5bd2de9a5a834ca988a558fc67cada02
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
ObjectiveCurrent treatment agents for HCC are mostly immune checkpoint inhibitors (ICIs) plus bevacizumab and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PF
Externí odkaz:
https://doaj.org/article/5db4c7f40b514a51a937f58df7d10bbc
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background In the existing next generation sequencing (NGS) system, epidermal growth factor receptor (EGFR) exon 19 deletion-insertion (19delins) is still interpreted into the category of EGFR exon 19 deletion (19del). However, the controver
Externí odkaz:
https://doaj.org/article/f563a95006724209905667bab22efc65
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
V-Raf murine sarcoma viral oncogene homolog B (BRAF) kinase, which was encoded by BRAF gene, plays critical roles in cell signaling, growth, and survival. Mutations in BRAF gene will lead to cancer development and progression. In non-small cell lung
Externí odkaz:
https://doaj.org/article/333709efe1f047d099c613657a6fe365
Publikováno v:
Chinese Journal of Lung Cancer, Vol 22, Iss 5, Pp 299-305 (2019)
Background and objective Adenocarcinoma is the most common type of lung cancer. It has been clinically evaluated that therapiestargeting against the epidermal growth factor receptor (EGFR) as the clinical standard first-line treatment. The response a
Externí odkaz:
https://doaj.org/article/9869fdde546943a0bdca33963ff8ed0e
Publikováno v:
Chinese Journal of Lung Cancer, Vol 22, Iss 3, Pp 137-142 (2019)
Background and objective Human epidermal growth factor receptor 2 (HER2) is one of the driver genes of non-small cell lung cancer (NSCLC). Several studies have shown that the efficacy of pemetrexed in HER2-mutant NSCLC is controversial. The aim of th
Externí odkaz:
https://doaj.org/article/de3c5a0914504d7e978c6323af2697d5